AMGN compared with EDIT: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

EDITEditas Medicine, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

EDITEditas Medicine, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

EDIT: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only EDIT 11

VRTXVertex Pharmaceuticalscustomer

BMYBristol Myers Squibbcustomer

BEAMBeam Therapeuticscustomer

—The Broad Instituteunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

supplier

7 more · EDIT chain ›

Price

rebased to 0%

AMGN, solidEDIT, dashed

AMGNAmgen Inc

462.52▼−0.75%

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

EDITEditas Medicine, Inc.

2.70▲+0.97%

Regular sessionSep 2 '83

Mkt cap$410.1MRevenue$12MQ2 FY26Revenue—

Compare

Regular sessionSep 2 '83

AMGNAmgen Inc

EDITEditas Medicine, Inc.

462.52▼−0.75%

Price

2.70▲+0.97%

$251.9B

Mkt cap

$410.1M

Q2 FY26$10.1B

Revenue

$12MQ2 FY26

FY25$36.8B

Revenue

—

AMGN462.52▼−0.75%vsEDIT2.70▲+0.97%Regular sessionSep 2 '83